博雅生物
(300294)
| 流通市值:63.99亿 | | | 总市值:63.99亿 |
| 流通股本:5.04亿 | | | 总股本:5.04亿 |
| 利润表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 营业总收入 | 846,914,941.7 | 643,555,888.03 | 321,128,375.86 | 2,059,088,027.17 |
| 营业总成本 | 836,500,603.21 | 614,673,835.61 | 296,220,781.81 | 1,738,837,657.08 |
| 其他经营收益 | | | | |
| 营业利润 | 11,799,286.97 | 5,460,441.13 | 37,147,624.59 | 109,422,428.38 |
| 利润总额 | 800,853.23 | 3,426,035.43 | 36,003,508.55 | 103,878,495.08 |
| 净利润 | 60,588,264.83 | 50,884,883.53 | 30,033,392.25 | 112,638,772.02 |
| 每股收益 | | | | |
| 其他综合收益 | -13,172,038.35 | -10,184,885.93 | -5,943,787.21 | -5,885,761.41 |
| 综合收益总额 | 47,416,226.48 | 40,699,997.6 | 24,089,605.04 | 106,753,010.61 |
| 资产负债表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 流动资产: | | | | |
| 流动资产合计 | 5,036,863,942.34 | 5,012,033,338 | 4,954,223,849.13 | 5,233,637,231.14 |
| 非流动资产: | | | | |
| 非流动资产合计 | 3,214,039,398.68 | 3,271,822,146.5 | 3,451,863,453.36 | 3,392,542,141.39 |
| 资产总计 | 8,250,903,341.02 | 8,283,855,484.5 | 8,406,087,302.49 | 8,626,179,372.53 |
| 流动负债: | | | | |
| 流动负债合计 | 662,269,799.83 | 698,989,703.01 | 784,509,138.11 | 1,033,795,419.63 |
| 非流动负债: | | | | |
| 非流动负债合计 | 138,828,796.03 | 141,777,265.21 | 158,289,882.79 | 153,185,276.35 |
| 负债合计 | 801,098,595.86 | 840,766,968.22 | 942,799,020.9 | 1,186,980,695.98 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 7,450,001,518.28 | 7,441,840,077.06 | 7,461,923,537.63 | 7,437,646,428.78 |
| 股东权益合计 | 7,449,804,745.16 | 7,443,088,516.28 | 7,463,288,281.59 | 7,439,198,676.55 |
| 负债和股东权益合计 | 8,250,903,341.02 | 8,283,855,484.5 | 8,406,087,302.49 | 8,626,179,372.53 |
| 现金流量表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 1,081,532,972.97 | 706,619,011.8 | 349,111,915.07 | 1,856,187,215.04 |
| 经营活动现金流出小计 | 1,151,171,694.48 | 842,927,285.29 | 476,341,282.31 | 1,795,024,527.46 |
| 经营活动产生的现金流量净额 | -69,638,721.51 | -136,308,273.49 | -127,229,367.24 | 61,162,687.58 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 5,191,787,360.68 | 2,825,227,499.43 | 2,286,067,267.44 | 5,227,394,023.25 |
| 投资活动现金流出小计 | 5,166,555,273.7 | 3,010,468,913.25 | 2,468,543,430.76 | 5,908,308,549.07 |
| 投资活动产生的现金流量净额 | 25,232,086.98 | -185,241,413.82 | -182,476,163.32 | -680,914,525.82 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 11,230,000 | 11,230,000 | 11,230,000 | 48,035,988.7 |
| 筹资活动现金流出小计 | 47,885,520.99 | 44,157,399.49 | 4,424,857.87 | 203,105,364.17 |
| 筹资活动产生的现金流量净额 | -36,655,520.99 | -32,927,399.49 | 6,805,142.13 | -155,069,375.47 |
| 汇率变动对现金及现金等价物的影响 | -282,149.82 | -208,716.89 | -104,238.48 | -133,997.22 |
| 现金及现金等价物净增加额 | -81,344,305.34 | -354,685,803.69 | -303,004,626.91 | -774,955,210.93 |
| 期末现金及现金等价物余额 | 442,271,873.7 | 168,930,375.35 | 220,611,552.13 | 523,616,179.04 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | - | -354,685,803.69 | - | -774,955,210.93 |